bluebird seeks gene therapy trial restart after cancer scare
pharmaphorum
MARCH 10, 2021
bluebird bio is to ask regulators to restart clinical studies of its LentiGlobin for sickle cell disease, after an investigation concluded that a case of acute myeloid leukaemia (AML) was “very unlikely” to be caused by the gene therapy. bluebird bio’s Philip Gregory.
Let's personalize your content